Oculis Holding AG
OCS
Company Profile
Business description
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
Contact
Bahnhofstrasse 20
Zug6300
CHET: +41 417119325
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
49
Stocks News & Analysis
stocks
Picking dividend shares in 2026? Here’s where to look
A new report from Morningstar shows opportunities for income investors.
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
With outstanding long-term estimates, here’s what we think of Nvidia stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,834.00 | 88.40 | 1.01% |
| CAC 40 | 8,035.88 | 82.11 | 1.03% |
| DAX 40 | 23,443.71 | 280.79 | 1.21% |
| Dow JONES (US) | 46,138.77 | 47.03 | 0.10% |
| FTSE 100 | 9,573.96 | 66.55 | 0.70% |
| HKSE | 25,835.57 | 4.92 | 0.02% |
| NASDAQ | 22,564.23 | 131.38 | 0.59% |
| Nikkei 225 | 49,823.94 | 1,286.24 | 2.65% |
| NZX 50 Index | 13,439.40 | 112.50 | 0.84% |
| S&P 500 | 6,642.16 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,552.70 | 84.70 | 1.00% |
| SSE Composite Index | 3,931.05 | 15.69 | -0.40% |